CD274 and cancer: Although the development and use of PD-1 and PD-L1 inhibitors represent a major advancement in cancer therapy, offering hope for many patients with advanced or hard-to-treat cancers, side effects and resistance reduced the efficacy of PD-1/PD-L1 inhibitors in immunotherapy (93, 94).